Insider Transactions in Q1 2024 at Selecta Biosciences Inc (SELB)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,970,443
+5.63%
|
$1,970,443
$1.46 P/Share
|
|
Mar 18
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
19,844
+0.41%
|
$0
$0.61 P/Share
|
|
Mar 15
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
538,700
+1.42%
|
$0
$0.58 P/Share
|
|
Mar 14
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
650,372
+1.99%
|
$0
$0.54 P/Share
|
|
Mar 13
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
3,200
+3.08%
|
$0
$0.58 P/Share
|
|
Mar 12
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
1,200
+1.21%
|
$0
$0.61 P/Share
|
|
Mar 11
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
1,200
+1.23%
|
$0
$0.65 P/Share
|
|
Mar 08
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
4,800
+4.8%
|
$0
$0.66 P/Share
|
|
Feb 07
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
2,400
+2.59%
|
$0
$0.66 P/Share
|
|
Feb 06
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
800
+0.9%
|
$0
$0.65 P/Share
|
|
Jan 17
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
800
+0.91%
|
$0
$0.69 P/Share
|
|
Jan 02
2024
|
Michael Singer Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+38.19%
|
-
|
|
Jan 02
2024
|
Patrick J Zenner Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+43.28%
|
-
|
|
Jan 02
2024
|
Carrie Smith Cox Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+31.29%
|
-
|
|
Jan 02
2024
|
Nishan M De Silva Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+49.04%
|
-
|
|
Jan 02
2024
|
Milos Miljkovic Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
548,200
+50.0%
|
-
|
|
Jan 02
2024
|
Timothy A Springer Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+2.33%
|
-
|
|
Jan 02
2024
|
Timothy C Barabe Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+29.37%
|
-
|
|
Jan 02
2024
|
Aymeric Sallin Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+50.0%
|
-
|
|
Jan 02
2024
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,654,100
+48.63%
|
-
|
|
Jan 02
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
778,200
+50.0%
|
-
|
|
Jan 02
2024
|
Blaine Davis Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,424,000
+50.0%
|
-
|
|
Jan 02
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,531,000
+50.0%
|
-
|
|
Jan 02
2024
|
Murat Kalayoglu Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+29.0%
|
-
|